Agenus (NASDAQ:AGEN) is a biotechnology firm focused on discovering, developing, and commercializing a range of immunotherapy products for treating cancer and infectious diseases. The company's portfolio includes checkpoint antibodies, cell therapies, adjuvants, and vaccines aimed at stimulating the immune response to target and eliminate cancer cells or pathogens. Agenus is dedicated to advancing cure rates and survival for patients while reducing side effects, with a keen emphasis on leveraging its technology platforms to create innovative treatments. Their objective is to harness the power of the immune system to provide new therapeutic options for patients with serious diseases, continuously pushing the boundaries in the field of immunotherapy.